Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mymetics Corporation (MYMX)
Epalinges, CH
Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent. Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | 0.00% | +0.00% | 0.00% | 0.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+0.0% Q3'23: -71.5% (vs Q3'22)
-
EPS growth Biotechnology: +29.7%-170,112.8% Q3'23: -97,633.3% (vs Q3'22)
-
FCF margin FCF growth · Biotechnology: +16.2%-61,833.3% Q3'23: -905.7% (vs Q3'22)
-
EBIT margin Biotechnology: +0.0%-66,833.3% Q3'23: -1,092.3% (vs Q3'22)
-
ROIC Biotechnology: -16.1%-29.5% Q3'23: +310.2% (vs Q3'22)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q3'23: +0.0% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-36.18× Q3'23: -46.83× (vs Q3'22)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Tax ID #43-1225960 | — | 0.00% | — | — | — | — | IA | Missouri Corporation | 1998-02-10 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-04-09 | KEMPERS Ronald Hugo Gerard | Director | A-Award | A | Stock options | 5,000,000 | 0.02 | 115.0K | 17,000,000 | — | ↗ |
| 2013-12-27 | KEMPERS Ronald Hugo Gerard | Officer | D-Return | D | Stock Options | 3,000,000 | 0.02 | 60.0K | 12,000,000 | — | ↗ |
| 2013-10-04 | Fleury Sylvain | Officer | A-Award | A | Stock Options | 800,000 | 0.02 | 16.0K | 800,000 | — | ↗ |
| 2012-03-23 | PICKERING GRANT | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-03-23 | HENNEY CHRISTOPHER S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-08-01 | Martin Jacques Francois | Officer | A-Award | A | Incentive Stock Option | 500,000 | 0.14 | 70.0K | 500,000 | — | ↗ |
| 2010-08-01 | KEMPERS Ronald Hugo Gerard | Officer | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2010-07-08 | Martin Jacques Francois | Officer | S-Sale | A | Common Stock | 150,000 | 0.20 | 30.0K | 150,000 | — | ↗ |
| 2010-07-01 | KEMPERS Ronald Hugo Gerard | Officer | — | D | Incentive Stock Option | 250,000 | 0.19 | 47.5K | 0 | — | ↗ |
| 2010-06-17 | Stegmann Antonius Johannes | Officer | — | D | Stock Options | 4,000,000 | 0.02 | 80.0K | 0 | — | ↗ |
| 2009-12-31 | Fleury Sylvain | Officer | A-Award | A | Stock Options | 350,000 | 0.14 | 49.0K | 350,000 | — | ↗ |
| 2009-07-20 | ROCHET CHRISTIAN | Director | S-Sale | D | Common Stock | 1,917,276 | 0.17 | 334.2K | 5,459,862 | — | ↗ |
| 2008-06-23 | Stern Ernest M | Director | A-Award | A | Common Stock | 500,000 | 0.00 | — | 1,500,000 | — | ↗ |
| 2008-06-10 | Martin Jacques Francois | Officer | — | D | Mymetics Common Stock | 0 | 0.00 | — | 1,430,307 | — | ↗ |
| 2008-03-17 | Stern Ernest M | Director | A-Award | A | Common Stock | 500,000 | 0.00 | — | 1,500,000 | — | ↗ |
| 2008-01-21 | Stern Ernest M | Director | — | D | Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2007-07-02 | Staehelin Thomas | Director | — | I | Unsecured convertible note, 6/23/2006 | 190,000 | 0.10 | 19.0K | 0 | — | ↗ |
| 2007-06-18 | LUEBKE ERNST | Director / Officer | A-Award | A | Common Stock | 2,500,000 | 0.00 | — | 10,079,418 | — | ↗ |
| 2007-06-18 | Fleury Sylvain | Officer | — | D | Common Stock | 0 | 0.00 | — | 6,500,000 | — | ↗ |
| 2007-06-05 | ROCHET CHRISTIAN | Director / Officer | P-Purchase | A | Common Stock | 6,000,000 | 0.00 | — | 7,377,138 | — | ↗ |
| 2006-01-31 | Round Enterprises, Ltd. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 141,006,552 | — | ↗ |
| 2006-01-11 | KHD HUMBOLDT WEDAG INTERNATIONAL LTD. | 10% Owner | A-Award | A | Contractual Right | 2,500,000 | 0.00 | — | 0 | — | ↗ |
| 2005-05-10 | KHD HUMBOLDT WEDAG INTERNATIONAL LTD. | 10% Owner | J-Other | A | common stock, par value $0.01 per share | 2,500,000 | 0.00 | — | 3,500,000 | — | ↗ |
| 2005-02-16 | MFC BANCORP LTD | 10% Owner | — | I | Contractual Right | 500,000 | 0.00 | — | 0 | — | ↗ |
| 2003-08-11 | ROCHET CHRISTIAN | Director / Officer | — | D | common stock | 0 | 0.00 | — | 1,527,009 | — | ↗ |
| 2003-07-31 | ZIMMER ROBERT | Director / Officer | — | D | common stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-31 | LUBKE ERNST | Director / Officer | — | D | common stock | 0 | 0.00 | — | 4,079,417 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ronald Kempers | Chief Executive Officer, Chief Operating Officer, President & Chief Financial Officer | 313.2K | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MYMX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
